Skip to main content
IONIS PHARMACEUTICALS INC logo

IONIS PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · IONS ISIN · US4622221004 LEI · 549300SI4ZGLG0BLUZ92 US Manufacturing
Open in API
Filings indexed 1,796 across all filing types
Latest filing 2023-11-24 Capital/Financing Update
Country US United States of America
Listing US IONS

About IONIS PHARMACEUTICALS INC

https://www.ionis.com/

Ionis Pharmaceuticals, Inc. is a biopharmaceutical company that discovers and develops RNA- and DNA-targeted therapeutics. Leveraging its expertise in antisense technology and a deep understanding of genetics, the company creates novel medicines designed to treat a wide range of serious diseases. Its development pipeline and marketed products primarily address neurologic and cardiometabolic disorders, as well as other areas with high unmet patient needs, including rare diseases. The company's approach aims to provide new solutions for complex and often intractable conditions by targeting the root cause of disease at the genetic level.

Recent filings

Filing Released Lang Actions
S-3ASR
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 registration statement filed with the SEC, which is used for registering securities for sale to the public. It includes a prospectus describing the terms of the offering of common stock, use of proceeds, risk factors, plan of distribution, and other related information. This type of filing is primarily related to capital raising activities and updates on financing. It is not an annual report, earnings release, or any other type of financial or governance report. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, supporting a high confidence level.
2023-11-24 English
PRIMARY DOCUMENT
Director's Dealing
2023-11-17 English
Regulatory Filings 2023
Regulatory Filings
2023-11-15 English
IONIS PHARMACEUTICALS INC 10-Q 9-30-2023
Interim / Quarterly Report Q3 2023
2023-11-02 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 2, 2023, reporting the company's financial results for the quarter ended September 30, 2023. It specifically states that the company issued a press release announcing quarterly financial results and that the press release is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather announces the results and provides the press release as an exhibit. The length of the document is 4053 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document announcing financial results with a press release attached is classified as an Earnings Release (ER).
2023-11-02 English
PRIMARY DOCUMENT
Director's Dealing
2023-11-01 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.